Background Previous studies have investigated the prevalence of drug-drug interactions (DDIs) among the elderly in different care settings, but data describing the frequency and management of DDIs among acute geriatric patients appear to be absent. Objective The aim of this study was to investigate the severity and interdisciplinary management of DDIs in patients admitted to an acute geriatric ward. Methods The study was conducted at Oslo University Hospital, Norway, over a period of 19 weeks in 2010/11. On admission and daily during the hospital stay, prescribed medications were reviewed by pharmacists to identify DDIs with the aid of web-based databases. DDIs defined to be of potential clinical relevance, i.e., those classified as ''major'' (generally avoid) or ''moderate'' (precautions recommended), were following assessments by pharmacists presented at interdisciplinary meetings with geriatricians and nurses, and discussed in relation to the possible implementation of monitoring actions or changes in prescribing. The odds for prescribing changes were compared in relation to DDI type (''pharmacokinetic'' vs. ''pharmacodynamic'') and severity (''major'' vs. ''moderate''). The project group retrospectively assessed the possible causal relationships between hospitalizations and DDIs. Results The pharmacists identified 245 DDIs of major (n = 13) or moderate (n = 232) severity in 80 (63.5 %) of the 126 patients included on admission and/or during hospitalization. In 94 of 162 cases where the pharmacists alerted the geriatricians (58.0 %), prescribing changes or monitoring actions were implemented. Prescribing changes (n = 38) were performed significantly more often for major than for moderate DDIs [odds ratio (OR) 3.8; 95 % confidence interval (CI) 1.2-12.2, p = 0.03], and significantly more often for pharmacokinetic than for pharmacodynamic DDIs (OR 4.9; 95 % CI 2.2-10.9, p \ 0.01). For 28 of 126 patients (22.2 %), a causal relationship between hospitalizations and DDIs was assessed as ''possible''. Conclusions The present study shows that acute geriatric patients are frequently exposed to DDIs for which active management is recommended in order to avoid unfavorable clinical outcomes. The integration of pharmacists into interdisciplinary teams could prevent potentially severe DDIs in the elderly.
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Introduction
Adverse drug reactions (ADRs) represent a major concern, with implications for patient health and health economics [1] [2] [3] [4] [5] [6] . Studies have shown that ADRs possibly cause about one-tenth of all hospital admissions [4, 7, 8] . ADRs may occur for different reasons, including drug-drug interactions (DDIs). DDIs have been reported to be associated with risk of hospitalization and length of hospital stay [9] [10] [11] .
Since most DDIs are predictable, they represent an important cause of ADRs that could be prevented [4, 5] .
Elderly patients are especially vulnerable to ADRs due to age-related changes in pharmacokinetics and pharmacodynamics [12] [13] [14] . Aging entails a progressive loss of renal filtration and hepatic metabolism, resulting in decreased elimination rates of many drugs and metabolites. Moreover, reduced homeostatic mechanisms imply that the elderly are generally more sensitive to drug combinations with additive pharmacodynamic effects. In addition to the increased ''pharmacological'' vulnerability of the elderly, increased drug use with age elevates the risk of exposure to DDIs [15] .
The proportion of elderly patients that are exposed to DDIs is reported to be around 25-45 % in different care settings [16] [17] [18] . However, published information on DDIs among the elderly in an urgent medical setting seems to be absent. The aim of this study was therefore to examine the frequency and interdisciplinary management of potentially severe DDIs in acute geriatric patients.
Methods

Study Design and Setting
This prospective study was conducted at an acute geriatric ward of Oslo University Hospital (Ullevaal location), Norway. Two pharmacists associated with the ward (authors ML and SER) were responsible for identifying DDIs and attended interdisciplinary meetings with geriatricians and nurses. The author SER underwent practical training as a clinical pharmacist during the inclusion period, while the author ML had practiced as a clinical pharmacist for several years prior to the study.
Participant Selection
Patients admitted to the ward between September 13 (2010) and January 25 (2011) were invited to participate in the study. The patients gave written informed consent prior to inclusion. The study was approved by the Regional Committee for Medical and Health Research Ethics, the Privacy Ombudsman, and the Hospital Investigational Review Board.
The ward comprised two parallel subunits (each with 10 beds) with random patient allocation. Since the pre-round briefings took place at the same time, only patients from one of the subunits were included in the study.
Measurements
The occurrence and interdisciplinary management of ''major'' or ''moderate'' DDIs detected at admission and during hospitalization were measured as primary endpoints. In addition, a retrospective analysis of possible associations between hospitalizations and DDIs detected on admission, including those of ''minor'' severity, was performed as a secondary end-point.
Data Collection and Processing
The pharmacists reviewed the patients' medication lists on admission and during hospitalization. They also retrieved relevant clinical data from the medical records. Two electronic databases were used to identify potential DDIs: the Drug Information Database (DRUID; available at http://www.interaksjoner.no) and the Swedish, Finnish, INteraction X-referencing (SFINX; available at http:// www.janusinfo.se), both of Nordic origin. These were applied because they are the most commonly used DDI databases in Norway. Both databases were non-commercial and freely available when the study was carried out, but one month after the end of inclusion, access to SFINX via http://www.janusinfo.se was prevented for non-Swedish users.
The severities of the DDIs identified in the two databases were harmonized into three classes. DDIs defined in SFINX as category A (''no clinical significance'') or category B (''clinical significance unknown and/or vary'') were merged into one common ''minor'' relevance class (i.e., no regular actions required), which was regarded as equivalent to the lowest relevance category defined in DRUID (''academic interest''). Moreover, interactions defined as category C in SFINX (''clinically meaningful interaction that can be managed with for example dose adjustments'') was considered identical to category 2 in DRUID (''precautions required''). Finally, category D in SFINX (''should be avoided'') was identical to category 3 in DRUID (''should be avoided'').
DDIs identified by the pharmacists were classified into one of the three harmonized classifications: major, moderate, or minor clinical relevance, which in terms of recommended management reflect ''avoidance'', ''precaution'', or ''no action required''. In cases of inconsistency between the databases, the highest relevance classification was applied. The underlying mechanisms of the identified DDIs (pharmacokinetic, pharmacodynamic, or mixed/unknown) and potential clinical consequences (increased or reduced pharmacological response) were also registered by the pharmacists.
Screening for DDIs was conducted both on admission and regularly during the hospital stay. The pharmacists examined the medication lists daily during the hospital stay except on Saturdays and Sundays. Screening for potential new DDIs was conducted when changes in drug prescribing were performed. A standard form was designed for registration of the detected DDIs and the respective decisions regarding further management. Information of possible relevance to the assessment of the individual interaction risk was also registered on the forms. This latter information was obtained from the medical records.
All major or moderate DDIs were eligible for discussion at interdisciplinary meetings, but in each case the pharmacists made individual risk assessments based on factors such as treatment history, laboratory measurements, and dose intensities of involved drugs prior to the meetings. DDIs which were considered to be sufficiently important that they required evaluation by the team were presented by the pharmacists at interdisciplinary meetings and discussed with geriatricians and nurses. The pharmacists were the same throughout the study period, while the geriatriciannurse team changed according to the duty plan.
At the interdisciplinary meetings, the pharmacists also presented possible solutions on how to manage the respective DDIs. The geriatricians decided in each case whether actions to manage the DDI should be implemented or not. Possible actions comprised (1) immediate prescribing changes in terms of drug withdrawal/addition, dose adjustment, or a switch to a non-interacting drug alternative, or (2) monitoring clinical signs, symptoms and/ or laboratory values to determine whether future treatment adjustment was needed. All decisions made by the geriatricians during interdisciplinary meetings were recorded by the pharmacists.
After the inclusion of the patients, the project group, consisting of two geriatricians (authors RK and TBW) and three pharmacists (authors ML, SER, and EM), performed qualitative assessments of causal relationships between hospitalizations and DDIs. No structured tool or score model for probability assessments was applied in this process. Instead, information on the reason(s) for hospitalization was compared with the potential clinical consequences of the DDIs detected at admission. If potential clinical consequences of a DDI could be linked to the clinical features (symptoms) of the hospitalization, a causal relationship was assessed as ''possible''. If not, a causal relationship was assessed as ''unlikely''.
When assessing the causal relationship between DDIs and hospitalizations, all DDIs were included regardless of their severity categories in the electronic databases. The overall proportion of the DDIs that were possibly linked to hospitalizations, and the respective distribution of severity categories, were calculated.
Data Analysis
To characterize the patient population, descriptive statistics (median values with ranges) were calculated for the following variables: age, number of prescribed drugs on admission, number of diagnoses, and days of hospitalization. In addition, a non-parametric correlation analysis between the number of regularly prescribed drugs at admission and DDIs identified as being of major or moderate severity was carried out (Spearman's test). Finally, Fisher's exact tests were run to compare the odds for prescribing changes in relation to DDI type (pharmacokinetic vs. pharmacodynamic) and DDI severity (major vs. moderate). Data from these latter analyses were presented as odds ratios (OR) with 95 % confidence intervals (CI). GraphPad prism version 5 (GraphPad Software Inc., La Jolla, CA, USA) was used for statistical analyses.
Results
In total, 126 patients were included during the study period. Table 1 provides demographic information about the included patients. Most of them were living at home without daily care (n = 67, 53.2 %), and only six (4.8 %) arrived from nursing homes. Approximately one-third of the patients (n = 39) had previously been admitted to the acute geriatric ward. Four patients died during the hospital stay.
Hypertension and cognitive failure were the most prevalent diagnoses at admission. These were present in 64 and 57 of the patients, respectively. Falls (n = 46), infection (n = 32), confusion (n = 22), and brain or myocardial infarction (n = 15) were the most frequent reasons for hospitalization. Inhibitors of platelet aggregation were the most commonly prescribed drugs, followed by benzodiazepines or benzodiazepine-like agents (Table 2 ). These were used by 64 (50.8 %) and 40 (31.7 %) of the patients, respectively.
Frequency and Severity of DDIs
In total, 450 DDIs were identified in 98 (77.8 %) of the 126 patients included at admission and/or during their hospital stay. Of the overall number of DDIs detected, 245 (54.4 %) were classified either as major (n = 13) or moderate (n = 232) in at least one of the two interaction databases. The major/moderate DDIs represented 131 different drug combinations, of which 56 (42.7 %) were defined in both databases with either of these severity categories. There was a significant correlation between the number of regularly prescribed drugs and the overall number of major or moderate DDIs identified at admission (Spearman r = 0.57, P \ 0.0001). The individual agents most often involved in DDIs of major or moderate severity were warfarin (n = 50), aspirin (acetylsalicylic acid, n = 18), and digitoxin (n = 12). The latter of these was, until recently, used instead of digoxin in Norway. At hospital admission, the pharmacists identified major or moderate DDIs in 60 of the 126 patients (47.6 %). During the hospital stay, DDIs of major or moderate severity were introduced in 50 patients, of whom 20 were not exposed to DDIs at admission. A total of 80 patients (63.5 %) were therefore exposed to major or moderate DDIs at admission and/or during the hospital stay. Table 3 provides an overview of the underlying interaction mechanisms and potential clinical consequences of the major and moderate DDIs identified at admission or during hospitalization. Most of the identified cases had an underlying pharmacodynamic interaction mechanism (n = 149; 60.8 %), while DDIs with pharmacokinetic or unknown/mixed interaction mechanisms each represented 48 cases (19.6 %). Overall, the vast majority of the DDIs implied an increased risk of side effects due to elevated pharmacological response(s) (n = 185; 75.5 %).
Increased risk of bleeding (59 cases) or excessive sedation/reduced attention (33 cases) were the most frequent types of risks associated with the identified major/ moderate DDIs (Table 4) . Warfarin was involved in 48 cases of increased risk of bleeding, whereas excessive sedation/reduced attention included 23 cases of combinations of diazepam (n = 10) or oxazepam (n = 13) with potent opioid analgesics (Table 4) .
Management of DDIs
The pharmacists presented 162 of 245 DDIs (66.1 %) that were identified as being of major or moderate severity at the interdisciplinary meetings. The remaining 83 cases were not discussed because they had already been addressed (n = 47, 19.2 %) or appeared to be under control (n = 36, 14.7 %). Of the DDIs that were addressed by the geriatricians prior to pharmaceutical review, most had an underlying pharmacodynamic mechanism (n = 32, 78.7 %). With respect to severity, the geriatricians had managed six of the 13 major DDIs (46.2 %) and 41 of the 232 moderate DDIs (17.7 %) prior to pharmaceutical review.
The geriatricians implemented risk-preventive actions for 94 of the 162 DDIs (58.0 %) that were presented by the pharmacists at the interdisciplinary meetings. In 38 cases, prescribing changes were immediately performed to prevent interaction risks. Drug discontinuations (21 cases) and dose adjustments (12 cases) were the most frequent prescribing changes performed to avoid interaction risks. Prescribing changes following notification from the pharmacists were performed significantly more often by the geriatricians for major than for moderate DDIs, and significantly more often for pharmacokinetic than for pharmacodynamic DDIs (Table 5) .
Monitoring of treatment was implemented as a riskpreventive action by the geriatricians in 56 cases following notification from the pharmacists (38.4 %). No actions were performed in the remaining 68 cases presented by the pharmacists (42.0 %) at the interdisciplinary meetings because the geriatricians considered it unlikely that the DDIs were of clinical relevance for the respective patients.
DDIs and Hospital Admissions
In 28 (22.2 %) of 126 patients, the DDIs identified at hospital admission were retrospectively considered to have a possible causal relationship with the hospitalization. For nine of these patients, multiple DDIs were possibly linked to the hospitalization. With respect to distribution in relation to defined severity in the electronic databases, the project group assessed it as possible that a causal relationship with the hospitalizations was present for 16 of 111 minor DDIs (14.5 %), 26 of 127 moderate DDIs (20.5 %), and two of six major DDIs (33.3 %). Dizziness/falls (8 patients) and elevated international normalized ratio/ bleedings (8 patients) were the potential consequences of the DDIs that most often coincided with the symptoms/ causes of hospitalization.
Discussion
In the present study, we found that the majority of the patients admitted to an acute geriatric ward were exposed to DDIs for which actions are recommended to avoid unwanted clinical consequences. Only a minor proportion of the DDIs were managed by geriatricians prior to pharmaceutical review, and the pharmacist-guided use of electronic databases to identify DDIs resulted in the implementation of risk-preventive actions in more than 50 % of the cases assessed to be of potential clinical relevance.
To our knowledge, this is the first study to investigate the frequency of DDIs in elderly patients admitted to an acute geriatric ward. DDIs of major or moderate severity were identified in more than 60 % of the patients at admission and/or during the hospital stay. This frequency is somewhat higher than those reported in previous studies with elderly patients in primary care [16] [17] [18] . The higher frequency of DDIs observed in the present study might reflect the urgent medical care setting, which implies that the patients admitted are often frail with complex diseases and treatment regimens. This latter is supported by studies in hospitalized geriatric patients where DDIs have been reported to occur in 60-80 % of the patients [19, 20] . Warfarin ? paracetamol (acetaminophen) (9) Warfarin ? NSAIDs or systemic corticosteroids (6) Warfarin ? simvastatin (5) Warfarin ? tramadol (3) Warfarin ? aspirin (acetylsalicylic acid) (3) Aspirin (acetylsalicylic acid) ? SSRIs (7) Aspirin (acetylsalicylic acid) ? NSAIDs (4) Excessive sedation, reduced attention, or increased fall risk (33)
Diazepam ? ketobemidone (4) Diazepam ? morphine (3) Diazepam ? oxycodone (3) Oxazepam ? morphine (5) Oxazepam ? ketobemidone (3) Oxazepam ? oxycodone (3) Oxazepam ? fentanyl (2) Midazolam ? buprenorphine (2) Unwanted reactions due to electrolyte disturbances (22) Digitoxin ? loop diuretics (12) Digitoxin ? hydrochlorothiazide (3)
Hydrochlorothiazide ? SSRIs or carbamazepine (5) Reduced antihypertensive effect (19) Loop diuretics or hydrochlorothiazide ?
NSAIDs (6) ACE inhibitors or AII receptor blockers ? NSAIDs (2) NSAIDs non-steroidal anti-inflammatory drugs, SSRIs selective serotonin reuptake inhibitors, ACE angiotensin-converting enzyme, AII angiotensin II
The identification of DDIs in a high proportion of the patients in our study may also be related to the utilization of two electronic databases. Actually, less than 50 % of the 131 drug combinations comprising all major or moderate DDIs detected in the study were included in both databases with either of these classifications. The limited consistency between the databases is thought-provoking, and is an issue for those who create DDI-alerting systems.
It was observed that moderate or major DDIs were introduced in 40 % of the patients during the hospital stay. This shows that prescribing changes performed after admission imply a substantial risk of exposing patients to new DDIs, which is in line with the results of previous studies [21, 22] . To avoid introducing DDIs as a consequence of hospitalization, it is crucial that strategies are implemented to ensure the quality and safety of the individual patient's medication during their hospital stay. Such strategies should include routine utilization of electronic databases to identify DDIs of potential relevance. However, it is a challenge to develop DDI-alerting systems that are relevant to clinical practice. The warnings could be too general and only important under certain conditions (e.g., high dose intensities, reduced organ functions, specific diseases, etc.). Moreover, because of co-morbidities, many interacting drug combinations may need to be used to achieve a therapeutic benefit, irrespective of warnings in DDI databases. It is therefore important that users of DDI databases are competent persons with the ability to assess the situation in relation to individual factors affecting the actual risk of identified DDIs.
In the present study, pharmacists were integrated into the interdisciplinary team to guide the identification, assessment, and management of DDIs. About 15 % of the identified DDIs of major or moderate severity were considered to be intended and/or under control and were therefore not presented to the geriatricians at the meetings. However, when the geriatricians were alerted, actions to prevent interaction risks were implemented in approximately 60 % of the cases. In most cases, monitoring actions were initiated for further clinical evaluation, but immediate changes in drug prescribing were also common (about 40 % of the actions). Not surprisingly, it was observed that prescribing changes were performed significantly more often for major than for moderate DDIs presented by the pharmacists. More unexpected was the fivefold higher frequency of prescribing changes observed for pharmacokinetic than for pharmacodynamic DDIs. This latter finding indicates that the recognition of pharmacokinetic DDIs requires more detailed pharmacological skills than the recognition of pharmacodynamic DDIs, and that pharmacokinetic DDIs are generally more likely to be missed by physicians. Overall, the results show that the interdisciplinary involvement of pharmacists in geriatric teams can be effective at preventing inappropriate prescribing in the elderly, which is consistent with a recent study by Zakrzewski-Jakubiak et al. [19] .
We retrospectively assessed DDIs to be a possible cause of hospitalization in approximately one-fifth of the included patients. However, the validity of this estimate is uncertain because a structured tool was not used to assess the relationships between DDIs and reasons for admission. On the other hand, the use of structured tools for probability assessments of potential side effects may be challenging in this type of patient population due to the complex and diffuse symptoms related to hospital admissions. To our knowledge, previous studies have not investigated the link between DDIs and hospitalizations in acute geriatric patients, but Doucet et al. [20] published a study in 1996 estimating that hospitalizations were caused by DDIs in 130 out of 1,000 geriatric patients (13 %). It is difficult to compare their findings with ours, but both studies illustrate that preventing DDIs in frail, elderly patients would be an important measure to adopt to reduce hospitalizations and ADRs in this population.
Around one-third of the DDIs assessed as having a possible causal relationship with hospitalizations in our study were classified as being of minor relevance. This may indicate that DDIs that are not considered to be of clinical relevance on a general basis could potentially cause serious ADRs in frail, elderly patients with an urgent need for care. To assess and manage DDIs in an acute geriatric setting, it is therefore essential that skilled professional evaluations of individual risks are combined with the standardized information provided in interaction databases. This professional role could be served by interdisciplinary cooperation between geriatricians and clinical pharmacists; indeed, such cooperation has been shown to significantly reduce the re-admission rate by approximately 50 % in patients above 80 years [23] . An important limitation of our study was the lack of information about self-medication and the use of medication lists at the hospital as the sole basis for database searches. Discrepancies between medication lists at the hospitals and the drugs actually used by the patients are a well-known phenomenon. Together with the limited number of patients included, this implies that the reported frequencies of DDIs in the current study are uncertain. Regarding our observations on the practical management of the DDIs, it should be noted that factors such as personal skills, the involvement of only two pharmacists, and the interpersonal and professional relations between the pharmacists and the physicians may have biased our results. Nevertheless, the findings of this study leave little doubt that the integration of pharmacists into interdisciplinary teams could play an important role in preventing potentially severe DDIs in elderly patients.
Conclusion
The present study shows that acute geriatric patients are frequently exposed to DDIs for which preventive actions are generally recommended to avoid unfavorable clinical outcomes. DDIs are not only common in this population on admission; many cases also occur during hospitalization. Integrating pharmacists into interdisciplinary teams could lead to reduced prevalence and improved management of DDIs in geriatric patients.
